NO330798B1 - Polypeptid, nukleinsyre, vektor, virus, antistoff, farmasoytisk preparat samt fremgangsmate for fremstilling og screening - Google Patents
Polypeptid, nukleinsyre, vektor, virus, antistoff, farmasoytisk preparat samt fremgangsmate for fremstilling og screening Download PDFInfo
- Publication number
- NO330798B1 NO330798B1 NO20023783A NO20023783A NO330798B1 NO 330798 B1 NO330798 B1 NO 330798B1 NO 20023783 A NO20023783 A NO 20023783A NO 20023783 A NO20023783 A NO 20023783A NO 330798 B1 NO330798 B1 NO 330798B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- nucleic acid
- polypeptide
- proteins
- domain
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 23
- 150000007523 nucleic acids Chemical class 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 21
- 108020004707 nucleic acids Proteins 0.000 title claims description 21
- 102000039446 nucleic acids Human genes 0.000 title claims description 21
- 239000013598 vector Substances 0.000 title claims description 17
- 229920001184 polypeptide Polymers 0.000 title claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 9
- 238000012216 screening Methods 0.000 title claims description 9
- 241000700605 Viruses Species 0.000 title claims description 5
- 102100036439 Amyloid beta precursor protein binding family B member 1 Human genes 0.000 claims description 53
- 101150077118 Hnrnpl gene Proteins 0.000 claims description 27
- 230000003993 interaction Effects 0.000 claims description 26
- 101100243745 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ptb1 gene Proteins 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 55
- 239000013612 plasmid Substances 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 54
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000001086 cytosolic effect Effects 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 101001135344 Homo sapiens Polypyrimidine tract-binding protein 1 Proteins 0.000 description 7
- 102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101000928670 Homo sapiens Amyloid beta precursor protein binding family B member 1 Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000004850 protein–protein interaction Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100039556 Galectin-4 Human genes 0.000 description 4
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000010396 two-hybrid screening Methods 0.000 description 4
- 102100040016 Amyloid-beta A4 precursor protein-binding family B member 3 Human genes 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100033658 Alpha-globin transcription factor CP2 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 101710149553 Amyloid-beta A4 precursor protein-binding family B member 3 Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102100022036 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102100036438 Amyloid beta precursor protein binding family B member 2 Human genes 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010059397 ENA-VASP proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150103317 GAL80 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101000800875 Homo sapiens Alpha-globin transcription factor CP2 Proteins 0.000 description 1
- 101000928680 Homo sapiens Amyloid beta precursor protein binding family B member 2 Proteins 0.000 description 1
- 101000959823 Homo sapiens Amyloid-beta A4 precursor protein-binding family B member 3 Proteins 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101100048228 Homo sapiens UBP1 gene Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 101100269970 Mus musculus Apbb1 gene Proteins 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100117629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LCB3 gene Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710103765 Transcription factor CP2 Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 102100040065 Upstream-binding protein 1 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940047127 fiore Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000003165 hybrid screening Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Soft Magnetic Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0001628A FR2804962B1 (fr) | 2000-02-10 | 2000-02-10 | Partenaires du domaine ptb1 de fe65, preparation et utilisations |
| US19850000P | 2000-04-18 | 2000-04-18 | |
| PCT/FR2001/000361 WO2001059104A1 (fr) | 2000-02-10 | 2001-02-07 | Partenaires du domaine ptb1 de fe65, preparation et utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023783D0 NO20023783D0 (no) | 2002-08-09 |
| NO20023783L NO20023783L (no) | 2002-09-09 |
| NO330798B1 true NO330798B1 (no) | 2011-07-18 |
Family
ID=26212162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023783A NO330798B1 (no) | 2000-02-10 | 2002-08-09 | Polypeptid, nukleinsyre, vektor, virus, antistoff, farmasoytisk preparat samt fremgangsmate for fremstilling og screening |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6696273B2 (es) |
| EP (1) | EP1257642B1 (es) |
| KR (1) | KR100802687B1 (es) |
| AT (1) | ATE415476T1 (es) |
| AU (2) | AU3562501A (es) |
| BR (1) | BR0108247A (es) |
| CA (1) | CA2399939A1 (es) |
| CY (1) | CY1108758T1 (es) |
| DE (1) | DE60136688D1 (es) |
| DK (1) | DK1257642T3 (es) |
| ES (1) | ES2315273T3 (es) |
| IL (1) | IL151147A0 (es) |
| MX (1) | MXPA02007620A (es) |
| NO (1) | NO330798B1 (es) |
| NZ (1) | NZ520697A (es) |
| PT (1) | PT1257642E (es) |
| WO (1) | WO2001059104A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10146737A1 (de) * | 2001-09-22 | 2003-04-10 | Aventis Pharma Gmbh | Coniosulfide und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389526A (en) * | 1989-11-02 | 1995-02-14 | Slade; Martin B. | Plasmid vectors for cellular slime moulds of the genus dictyostelium |
| US5928882A (en) * | 1997-10-24 | 1999-07-27 | The Rockefeller University | Treatment and prevention of neurodegenerative diseases using modulators of Fe65 |
| AU1536399A (en) * | 1997-11-26 | 1999-06-15 | Genetics Institute Inc. | Secreted proteins and polynucleotides encoding them |
| US6214582B1 (en) * | 1998-11-16 | 2001-04-10 | The Research Foundation Of State University Of Ny | Y2H35 a strong IKK binding protein |
-
2001
- 2001-02-07 AT AT01907727T patent/ATE415476T1/de active
- 2001-02-07 WO PCT/FR2001/000361 patent/WO2001059104A1/fr active IP Right Grant
- 2001-02-07 IL IL15114701A patent/IL151147A0/xx unknown
- 2001-02-07 PT PT01907727T patent/PT1257642E/pt unknown
- 2001-02-07 MX MXPA02007620A patent/MXPA02007620A/es active IP Right Grant
- 2001-02-07 AU AU3562501A patent/AU3562501A/xx active Pending
- 2001-02-07 ES ES01907727T patent/ES2315273T3/es not_active Expired - Lifetime
- 2001-02-07 BR BR0108247-7A patent/BR0108247A/pt not_active IP Right Cessation
- 2001-02-07 NZ NZ520697A patent/NZ520697A/en not_active IP Right Cessation
- 2001-02-07 DE DE60136688T patent/DE60136688D1/de not_active Expired - Lifetime
- 2001-02-07 CA CA002399939A patent/CA2399939A1/fr not_active Abandoned
- 2001-02-07 KR KR1020027010351A patent/KR100802687B1/ko not_active IP Right Cessation
- 2001-02-07 DK DK01907727T patent/DK1257642T3/da active
- 2001-02-07 EP EP01907727A patent/EP1257642B1/fr not_active Expired - Lifetime
- 2001-02-07 AU AU2001235625A patent/AU2001235625B2/en not_active Ceased
- 2001-02-09 US US09/780,996 patent/US6696273B2/en not_active Expired - Fee Related
-
2002
- 2002-08-09 NO NO20023783A patent/NO330798B1/no not_active IP Right Cessation
-
2003
- 2003-12-03 US US10/726,721 patent/US6942982B2/en not_active Expired - Fee Related
-
2009
- 2009-02-05 CY CY20091100140T patent/CY1108758T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL151147A0 (en) | 2003-04-10 |
| EP1257642B1 (fr) | 2008-11-26 |
| DE60136688D1 (de) | 2009-01-08 |
| BR0108247A (pt) | 2002-11-05 |
| AU2001235625B2 (en) | 2007-01-11 |
| CY1108758T1 (el) | 2014-04-09 |
| ES2315273T3 (es) | 2009-04-01 |
| NO20023783L (no) | 2002-09-09 |
| MXPA02007620A (es) | 2002-12-13 |
| PT1257642E (pt) | 2009-01-30 |
| EP1257642A1 (fr) | 2002-11-20 |
| US6696273B2 (en) | 2004-02-24 |
| NZ520697A (en) | 2005-11-25 |
| WO2001059104A1 (fr) | 2001-08-16 |
| KR20020079844A (ko) | 2002-10-19 |
| US6942982B2 (en) | 2005-09-13 |
| US20040166109A1 (en) | 2004-08-26 |
| NO20023783D0 (no) | 2002-08-09 |
| US20020061553A1 (en) | 2002-05-23 |
| DK1257642T3 (da) | 2009-03-30 |
| ATE415476T1 (de) | 2008-12-15 |
| CA2399939A1 (fr) | 2001-08-16 |
| KR100802687B1 (ko) | 2008-02-12 |
| AU3562501A (en) | 2001-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guénette et al. | Association of a novel human FE65-like protein with the cytoplasmic domain of the beta-amyloid precursor protein. | |
| Elgersma et al. | The SH3 domain of the Saccharomyces cerevisiae peroxisomal membrane protein Pex13p functions as a docking site for Pex5p, a mobile receptor for the import PTS1-containing proteins. | |
| Feldheim et al. | Sec72p contributes to the selective recognition of signal peptides by the secretory polypeptide translocation complex. | |
| Akey et al. | The inherited blindness associated protein AIPL1 interacts with the cell cycle regulator protein NUB1 | |
| Freire | Translation initiation factor (iso) 4E interacts with BTF3, the β subunit of the nascent polypeptide-associated complex | |
| US6242201B1 (en) | Identification of the P21WaF1-PCNA interaction site and therapeutic applications thereof | |
| Fisher et al. | Role of interaction of XPF with RPA in nucleotide excision repair | |
| Lee et al. | Inhibition of APP intracellular domain (AICD) transcriptional activity via covalent conjugation with Nedd8 | |
| US7070940B2 (en) | Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein | |
| Marfatia et al. | Identification and characterization of the human MOG1 gene | |
| NO330798B1 (no) | Polypeptid, nukleinsyre, vektor, virus, antistoff, farmasoytisk preparat samt fremgangsmate for fremstilling og screening | |
| Le et al. | Monoclonal antibodies against the muscle-specific N-terminus of dystrophin: characterization of dystrophin in a muscular dystrophy patient with a frameshift deletion of exons 3-7. | |
| JP2003523723A (ja) | ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法 | |
| JP2002542774A (ja) | タンパク質−タンパク質相互作用 | |
| JP4745583B2 (ja) | Ｆｅｂ６５のｐｔｂ１ドメインのパートナー、製造及び使用 | |
| WO2005103257A1 (ja) | RhoAと結合するグアニンヌクレオチド交換因子をコードする遺伝子 | |
| EP0900384A2 (en) | Novel treatment | |
| AU9354998A (en) | Nucleic acids coding for proteins capable of interacting with presenilins | |
| JP4232423B2 (ja) | 新規ユビキチン特異プロテアーゼ | |
| EP1033402A1 (en) | p16-BINDING PROTEINS, GENE THEREOF, AND ANTIBODY THEREAGAINST | |
| KR20020089352A (ko) | 파킨 유전자 활성의 조절에 유용한 조성물 | |
| AU1391700A (en) | Polypeptides capable of interacting with the human topoisomerase iii alpha | |
| Catlett | Role of a yeast myosin-V in movement of the vacuole and other cargoes | |
| America et al. | The SH3 Domain of the Saccharomyces cerevisiae Peroxisomal Membrane Protein Pex13p Functions as | |
| Andag et al. | Dsl1p, an essential component of the Golgi-ER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |